Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer

Published on Jan 1, 2021in Gastroenterology22.682
· DOI :10.1053/J.GASTRO.2020.09.043
Jennifer P. Morton57
Estimated H-index: 57
(Glas.: University of Glasgow),
Owen J. Sansom93
Estimated H-index: 93
(Glas.: University of Glasgow)
BACKGROUND & AIMS Continuing recalcitrance to therapy cements pancreatic cancer (PC) as the most lethal malignancy, which is set to become the second leading cause of cancer death in our society. The study aim was to investigate the association between DNA damage response (DDR), replication stress, and novel therapeutic response in PC to develop a biomarker-driven therapeutic strategy targeting DDR and replication stress in PC. METHODS We interrogated the transcriptome, genome, proteome, and functional characteristics of 61 novel PC patient-derived cell lines to define novel therapeutic strategies targeting DDR and replication stress. Validation was done in patient-derived xenografts and human PC organoids. RESULTS Patient-derived cell lines faithfully recapitulate the epithelial component of pancreatic tumors, including previously described molecular subtypes. Biomarkers of DDR deficiency, including a novel signature of homologous recombination deficiency, cosegregates with response to platinum (P < .001) and PARP inhibitor therapy (P < .001) in vitro and in vivo. We generated a novel signature of replication stress that predicts response to ATR (P < .018) and WEE1 inhibitor (P < .029) treatment in both cell lines and human PC organoids. Replication stress was enriched in the squamous subtype of PC (P < .001) but was not associated with DDR deficiency. CONCLUSIONS Replication stress and DDR deficiency are independent of each other, creating opportunities for therapy in DDR-proficient PC and after platinum therapy.
📖 Papers frequently viewed together
16 Authors (Sandeep Kumar, ..., Guang Peng)
#1Stephan Dreyer (Glas.: University of Glasgow)H-Index: 11
#2Mark Pinese (Garvan Institute of Medical Research)H-Index: 33
Last. David K. ChangH-Index: 49
view all 36 authors...
Objective: We aimed to define preoperative clinical and molecular characteristics that would allow better patient selection for operative resection. Background: Although we use molecular selection methods for systemic targeted therapies, these principles are not applied to surgical oncology. Improving patient selection is of vital importance for the operative treatment of pancreatic cancer (pancreatic ductal adenocarcinoma). Although surgery is the only chance of long-term survival, 80% still su...
#1Wungki ParkH-Index: 14
#2Jiapeng Chen (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Last. Imane El Dika (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 10
view all 31 authors...
Purpose: Genomic methods can identify homologous recombination deficiency (HRD). Rigorous evaluation of their outcome association to DNA damage response–targeted therapies like platinum in pancreatic ductal adenocarcinoma (PDAC) is essential in maximizing therapeutic outcome. Experimental Design: We evaluated progression-free survival (PFS) and overall survival (OS) of patients with advanced-stage PDAC, who had both germline- and somatic-targeted gene sequencing. Homologous recombination gene mu...
Abstract Background Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate–ribose) polymerase (PARP) in...
#1Carlo MaurerH-Index: 2
#2Sam R. HolmstromH-Index: 11
Last. Kenneth P. OliveH-Index: 28
view all 16 authors...
Objective Pancreatic ductal adenocarcinoma (PDA) has among the highest stromal fractions of any cancer and this has complicated attempts at expression-based molecular classification. The goal of this work is to profile purified samples of human PDA epithelium and stroma and examine their respective contributions to gene expression in bulk PDA samples. Design We used laser capture microdissection (LCM) and RNA sequencing to profile the expression of 60 matched pairs of human PDA malignant epithel...
#1Stephan Dreyer (Glasgow Royal Infirmary)H-Index: 11
#2Nigel B. Jamieson (Glasgow Royal Infirmary)H-Index: 45
Last. David K. Chang (Glasgow Royal Infirmary)H-Index: 49
view all 14 authors...
Next-generation sequencing is enabling molecularly guided therapy for many cancer types, yet failure rates remain relatively high in pancreatic cancer (PC). The aim of this study is to investigate the feasibility of genomic profiling using endoscopic ultrasound (EUS) biopsy samples to facilitate personalised therapy for PC. Ninty-five patients underwent additional research biopsies at the time of diagnostic EUS. Diagnostic formalin-fixed (FFPE) and fresh frozen EUS samples underwent DNA extracti...
#1Eric A. Collisson (UCSF: University of California, San Francisco)H-Index: 44
#2Peter Bailey (Glas.: University of Glasgow)H-Index: 41
Last. Andrew V. Biankin (Glas.: University of Glasgow)H-Index: 76
view all 4 authors...
Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic st...
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 68
#2Kimberly D. Miller (ACS: American Cancer Society)H-Index: 29
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
view all 3 authors...
: Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2015, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2016, were collected by the Nati...
#1Thierry ConroyH-Index: 52
#2Pascal HammelH-Index: 87
Last. James Joseph Biagi (University of Lorraine)H-Index: 19
view all 32 authors...
Abstract Background Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall surviv...
#31Anthony J. GillH-Index: 76
#32Marina Pajic (UNSW: University of New South Wales)H-Index: 38
Objective Extensive molecular heterogeneity of pancreatic ductal adenocarcinoma (PDA), few effective therapies and high mortality make this disease a prime model for advancing development of tailored therapies. The p16-cyclin D-cyclin-dependent kinase 4/6-retinoblastoma (RB) protein (CDK4) pathway, regulator of cell proliferation, is deregulated in PDA. Our aim was to develop a novel personalised treatment strategy for PDA based on targeting CDK4. Design Sensitivity to potent CDK4/6 inhibitor PD...
#1Francesco Puleo (ULB: Université libre de Bruxelles)H-Index: 10
#2Rémy NicolleH-Index: 13
Last. Raphaël Maréchal (ULB: Université libre de Bruxelles)H-Index: 23
view all 19 authors...
Background & Aims Genomic studies have revealed subtypes of pancreatic ductal adenocarcinoma (PDA) based on their molecular features, but different studies have reported different classification systems. It is a challenge to obtain high-quality, freshly frozen tissue for clinical analysis and determination of PDA subtypes. We aimed to redefine subtypes of PDA using a large number of formalin-fixed and paraffin-embedded PDA samples, which are more amenable to routine clinical evaluation. Methods ...
Cited By20
#1Byung Woog Kang (Kyungpook National University Hospital)H-Index: 19
#2Ian Chau (The Royal Marsden NHS Foundation Trust)H-Index: 72
Introduction null Despite the recent development of new chemotherapeutic regimens and combination strategies, metastatic pancreatic cancer (mPC) still shows only a modest response to conventional cytotoxic agents. However, several novel therapeutic agents targeting the unique features of mPC are showing promise in clinical trials. null Area covered null This article reviews the current state of development of new agents targeting various systems and molecular pathways. We searched PubMed and cli...
Last. Pierre CordelierH-Index: 31
view all 18 authors...
Chronic DNA replication stress and genome instability are two hallmarks of cancer that fuel oncogenesis and tumor diversity. Therapeutic approaches aimed to leverage tumor-specific replication stress to intolerable levels or to expose vulnerabilities for synthetic lethality purposes have recently gained momentum, especially for pancreatic cancer, a disease with no cure. However, the current knowledge regarding the molecular mechanisms involved in the replication stress response in pancreatic tum...
#1Maria Miquel (FAU: University of Erlangen-Nuremberg)
#2S. Zhang (FAU: University of Erlangen-Nuremberg)
Last. Christian Pilarsky (FAU: University of Erlangen-Nuremberg)H-Index: 67
view all 3 authors...
Pancreatic ductal adenocarcinoma (PDAC) is a hostile solid malignancy coupled with an extremely high mortality rate. Metastatic disease is already found in most patients at the time of diagnosis, resulting in a five-year survival rate below 5%. Improved comprehension of the mechanisms leading to metastasis is pivotal for the development of new targeted therapies. A key field to be improved are modeling strategies applied in assessing cancer progression, since traditional platforms fail in recapi...
#1J. Nathaniel Diehl (UNC: University of North Carolina at Chapel Hill)H-Index: 4
#2Jennifer E. Klomp (UNC: University of North Carolina at Chapel Hill)H-Index: 7
Last. Björn Papke (UNC: University of North Carolina at Chapel Hill)H-Index: 2
view all 18 authors...
Oncogenic KRAS drives cancer growth by activating diverse signaling networks, not all of which have been fully delineated. We set out to establish a system-wide profile of the KRAS-regulated kinase signaling network (kinome) in KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). We knocked down KRAS expression in a panel of six cell lines and then applied multiplexed inhibitor bead/MS to monitor changes in kinase activity and/or expression. We hypothesized that depletion of KRAS would result in...
#1Chengguo Li (HUST: Huazhong University of Science and Technology)H-Index: 4
#2Qian Shen (HUST: Huazhong University of Science and Technology)H-Index: 4
Last. Kaixiong Tao (HUST: Huazhong University of Science and Technology)H-Index: 29
view all 10 authors...
BACKGROUND Identification of genomic biomarkers to predict the anticancer effects of indicated drugs is considered a promising strategy for the development of precision medicine. DNA endonuclease MUS81 plays a pivotal role in various biological processes during malignant diseases, mainly in DNA damage repair and replication fork stability. Our previous study reported that MUS81 was highly expressed and linked to tumor metastasis in gastric cancer; however, its therapeutic value has not been full...
Pancreatic ductal adenocarcinoma is an aggressive disease for which there are very few available therapies. It is notable for its high degree of tumour complexity, with the tumour microenvironment often accounting for the majority of the tumour volume. Until recently, the biology of the stroma was poorly understood, particularly in terms of heterogeneity. Recent research, however, has shed light on the intricacy of signalling within the stroma and particularly the molecular and functional hetero...
#1Natalie Ngoi (University Health System)H-Index: 6
#2Melissa M. Pham (University of Texas MD Anderson Cancer Center)H-Index: 1
Last. Timothy A. YapH-Index: 26
view all 4 authors...
The replication stress response (RSR) involves a downstream kinase cascade comprising ataxia telangiectasia-mutated (ATM), ATM and rad3-related (ATR), checkpoint kinases 1 and 2 (CHK1/2), and WEE1-like protein kinase (WEE1), which cooperate to arrest the cell cycle, protect stalled forks, and allow time for replication fork repair. In the presence of elevated replicative stress, cancers are increasingly dependent on RSR to maintain genomic integrity. An increasing number of drug candidates targe...
#3Doga Gulhan (Harvard University)H-Index: 145
In a trial of patients with high grade serous ovarian cancer (HGSOC), addition of the ATR inhibitor berzosertib to gemcitabine improved progression free survival (PFS) compared to gemcitabine alone but biomarkers predictive of treatment are lacking. Here we report a candidate biomarker of response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in HGSOC ovarian cancer. Patients with replication stress (RS)-high tumors (n = 27), defined as harboring at least one genomic RS al...
#1Xiaofan Lu (CPU: China Pharmaceutical University)H-Index: 10
#2Jialin Meng (Anhui Medical University)H-Index: 8
Last. Hangyu Yan (CPU: China Pharmaceutical University)H-Index: 3
view all 12 authors...
Background: Hepatitis B virus (HBV), the main risk factor for hepatocellular carcinoma (HCC) development, integrates into the host genome, causing genetic instability, which may trigger malignancies to exhibit chronic DNA replication stress, providing exploitable therapeutic vulnerabilities. Therefore, customizing prognostication approach and expanding therapeutic options are of great clinical significance to HBV-associated HCCs. Methods: A robust machine-learning framework was designed to devel...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.